Outcome | Implementation group | Control group | Dashboard data | Combined control group | Implementation vs combined control | Implementation vs control group | ||
---|---|---|---|---|---|---|---|---|
n = 119 | n = 93 | n = 640 | n = 733 | Comparison (95% CI) | p value | Comparison (95% CI) | p value | |
Percentage time in therapeutic range—mean % (sd) | 62.74 (20.57) | 54.86 (20.70) | 55.31 (23.10) | 55.25 (22.79) | 7.49 (3.41 to 11.57)1 | 0.0004 6 | 7.89 (2.25 to 13.52)3 | 0.006 6 |
INR ≥ 4 during first week—n (%) | 2 (1.68) | 10 (10.75) | 44 (6.88) | 54 (7.37) | 0.21 (0.05 to 0.89)2 | 0.03 7 | 0.14 (0.03 to 0.66)4 | 0.01 7 |
INR < 2 during first week—n (%) | 91 (76.47) | 70 (75.27) | 338 (52.81) | 408 (55.66) | 2.59 (1.65 to 4.05)2 | < 0.0001 7 | 1.07 (0.57 to 2.01)4 | 0.84 7 |
Number of clinic visits—median (IQR) | 10 (8–11) | 10 (9–12) | 9 (8–13) | 10 (8–12) | – | 0.49 8 | – | 0.18 8 |
Number of adverse events | 19 | 0 | N/A | N/A | N/A | N/A | N/A | N/A |